Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INMT | O95050 | 4/20 | 1.00 |
| ▸ | USP2 | O75604 | 2/20 | 1.00 |
| ▸ | ACHE | P22303 | 6/20 | 0.38 |
| ▸ | NOS3 | P29474 | 4/20 | 0.36 |
| ▸ | NOS1 | P29475 | 4/20 | 0.36 |
| ▸ | NOS2 | P35228 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10601682 | 1.00 | INMT (1.00) | INMTUSP2ACHENOS3NOS1 | |
| SCHEMBL16583523 | 1.00 | INMT (1.00) | INMTUSP2ACHENOS3NOS1 | |
| SCHEMBL2401189 | 1.00 | INMT (1.00) | INMTUSP2ACHENOS3NOS1 | |
| SCHEMBL17417853 | 1.00 | INMT (1.00) | INMTUSP2ACHENOS3NOS1 | |
| SCHEMBL2734323 | 1.00 | INMT (1.00) | INMTUSP2ACHENOS3NOS1 | |
| SCHEMBL3047 | 1.00 | INMT (1.00) | INMTUSP2ACHENOS3NOS1 | |
| Iodide SCHEMBL23365018 | 0.98 | INMT (0.95) | INMTUSP2ACHENOS3NOS1 | |
| Ammonia Solution, Strong SCHEMBL6834929 | 0.98 | INMT (0.95) | INMTUSP2ACHENOS3NOS1 | |
| Bromide SCHEMBL8469764 | 0.98 | INMT (0.95) | INMTUSP2ACHENOS3NOS1 | |
| SCHEMBL2544511 | 0.98 | INMT (0.95) | INMTUSP2ACHENOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2838934-A2 | MOSITURE CURABLE ORGANOPOLYSILOXANE COMPOSITION | Momentive Performance Materials Inc. (US) | 2015-02-25 | — | — | EP | claimed |
| US-20150038632-A1 | MOISTURE CURABLE ORGANOPOLYSILOXANE COMPOSITION | MOMENTIVE PERFORMANCE MATERIALS INC. | 2015-02-05 | — | — | US | claimed |
| WO-2013158236-A2 | MOSITURE CURABLE ORGANOPOLYSILOXANE COMPOSITION | MOMENTIVE PERFORMANCE MATERIALS INC. (US) | 2013-10-24 | — | — | WO | claimed |
| EP-4569023-A1 | COMBINATION OF CATALYTIC COMPONENTS | PolyU GmbH (DE) | 2025-06-18 | — | — | EP | disclosed |
| WO-2024033348-A1 | COMBINATION OF CATALYTIC COMPONENTS | POLYU GMBH (DE) | 2024-02-15 | — | — | WO | disclosed |
| EP-4321573-A1 | COMBINATION OF CATALYTIC COMPONENTS | PolyU GmbH (DE) | 2024-02-14 | — | — | EP | disclosed |
| US-20230189639-A1 | COMPOUND FOR ORGANIC ELECTRONIC ELEMENT, ORGANIC ELECTRONIC ELEMENT USING THE SAME, AND AN ELECTRONIC DEVICE THEREOF | DUK SAN NEOLUX CO., LTD. (KR) | 2023-06-15 | — | — | US | disclosed |
| US-20210226142-A1 | UV CROSSLINKING OF PVDF-BASED POLYMERS FOR GATE DIELECTRIC INSULATORS OF ORGANIC THIN-FILM TRANSISTORS | CORNING INCORPORATED | 2021-07-22 | — | — | US | disclosed |
| US-20210135109-A1 | ACCELERATED THERMAL CROSSLINKING OF PVDF-HFP VIA ADDITION OF ORGANIC BASES, AND THE USAGE OF CROSSLINKED PVDF-HFP AS GATE DIELECTRIC MATERIAL FOR OTFT DEVICES | CORNING INCORPORATED | 2021-05-06 | — | — | US | disclosed |
| EP-3409709-B1 | PHOTOCURING METHOD, COMPOUND AND COMPOSITION USED THEREIN | FUJIFILM WAKO PURE CHEMICAL CORP (JP) | 2020-08-19 | — | — | EP | disclosed |
| EP-3677165-A1 | ENDOSCOPE ADHESIVE, CURED MATERIAL, ENDOSCOPE, AND METHOD FOR MANUFACTURING ENDOSCOPE | FUJIFILM Corporation (JP) | 2020-07-08 | — | — | EP | disclosed |
| US-6794530-B1 | 1,4-ADDITION OF MONOHYDRIC OR POLYHYDRIC ALCOHOLS TO ALPHA , BETA -UNSATURATED NITRILES | BASF AKTIENGESELLSCHAFT (DE) | 2004-09-21 | — | — | US | disclosed |
| EP-0919555-B1 | Process for the preparation of bicyclic amidines, diazacycloalkenes and a process for their preparation | BASF AG (DE) | 2002-05-08 | — | — | EP | disclosed |
| US-6166207-A | Preparation of bicyclic amidines and diazacycloalkenes | BASF AKTIENGESELLSCHAFT (DE) | 2000-12-26 | — | — | US | disclosed |
| US-6130347-A | REACTING MONOCHLOROACETIC ESTER WITH HYDROGEN CYANIDE IN BASE PRESENCE; CYANATION | BASF AKTIENGESELLSCHAFT (DE) | 2000-10-10 | — | — | US | disclosed |
| EP-0919555-A1 | Process for the preparation of bicyclic amidines, diazacycloalkenes and a process for their preparation | BASF AKTIENGESELLSCHAFT (DE) | 1999-06-02 | — | — | EP | disclosed |
| US-4943633-A | Catalytic preparation of cyanoalkyl lactams | AIR PRODUCTS AND CHEMICALS, INC. (US) | 1990-07-24 | — | — | US | disclosed |
| EP-0080171-B1 | HEAT-INSULATING MOULDING AND PROCESS FOR PREPARING THE SAME | Hitachi, Ltd. (JP) | 1988-06-08 | — | — | EP | disclosed |
| EP-0022519-B1 | PROCESS FOR THE PREPARATION OF A MIXTURE OF 2-HYDROXY AND 4-HYDROXY BENZYL ALCOHOL | BAYER AG (DE) | 1982-02-03 | — | — | EP | disclosed |
| US-4245126-A | FROM PHENOL AND PARAFORMALDEHYDE IN THE PRESENCE OF A CATALYST CONTAINING TWO OR MORE TERTIARY AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 1981-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230189639-A1 | COMPOUND FOR ORGANIC ELECTRONIC ELEMENT, ORGANIC ELECTRONIC ELEMENT USING THE SAME, AND AN ELECTRONIC DEVICE THEREOF | ETV6, OR51E2, NFE2L2 | INMT 1304/4885USP2 2564/4885ACHE 1097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.